Accessing Targeted Therapies: A Potential Roadblock to Implementing Precision Oncology?
Mitchell S von ItzsteinMary L SmithElda RaileyCarol B WhiteJulianne S DieterichElizabeth Garrett-MayerSuanna Steeby BruinoogeAndrew N FreedmanJanet S de MoorStacy W GrayJason Y ParkJingsheng YanAnh Quynh HoangHong ZhuDavid E GerberPublished in: JCO oncology practice (2021)
When NGS identifies an actionable result, a substantial proportion of clinicians reported encountering challenges obtaining approved therapies on the basis of these results. Perceived overall impact of NGS appears associated with clinical behavior unrelated to actionable NGS test results, including pursuing off-label or compassionate use of unapproved therapies or referring to a clinical trial.